Today: 27 January 2026
Subscribe
Browse Category

Healthcare Industry News 9 October 2025 - 6 November 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

What happened today Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. Novavax Revenue for the quarter came in at $70 million, above Wall…
6 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced…
5 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value Reuters. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations,…
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share Reuters. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding…
4 November 2025
···
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech Reportify. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits) Timesunion Reportify – a testament to investors’ optimism in AbbVie’s…
31 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecasts Marketscreener. Sales of Keytruda, its blockbuster cancer drug, grew about 10% (to $8.1 B) Marketscreener, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales…
30 October 2025
····
UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth’s recent earnings and strategic shifts have drawn close market attention. The company’s Q3 2025 results beat expectations, enabling a tighter outlook. Its revenue for Q3 rose 12% to $113.2 billion Unitedhealthgroup, with adjusted profit of $2.92 per share. That exceeded estimates and allowed management to raise full-year profit guidance. On Oct. 28, UnitedHealth said it now sees 2025 net EPS…
29 October 2025
····
Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron (NASDAQ: REGN) shares recently traded around $580–$585 (closing at $585.31 on Oct 27) after a slight pullback earlier in the month Investing. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s Investing. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion (+1% y/y), led by…
28 October 2025
····
Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Deal Details and Company Background Hologic (NYSE: HOLX) is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment (notably after its acquisition of Gynesonics), and lab diagnostics including molecular tests for Covid-19 Bostonglobe. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus…
21 October 2025
···
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 Marketbeat, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursday Vikingtherapeutics. This marks a dramatic recovery…
19 October 2025
···
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T:…
10 October 2025
····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approved Reuters. By then, the landscape may include other new NASH therapies (possibly Lilly’s or Madrigal’s), but Novo’s combination strategy could set it apart. Wolfe Research…
9 October 2025
·
1 … 7 8 9 10

Stock Market Today

  • Believe S.A. (BLV.PA) Pre-Market at €17.20 Eyes Oversold Bounce on EURONEXT
    January 26, 2026, 11:41 PM EST. Believe S.A. (BLV.PA) trades at €17.20 in EURONEXT pre-market, with volume near average at 19,984 shares. The stock shows a negative EPS of -0.03 and a price-to-earnings (P/E) ratio of -573.33, reflecting recent losses despite revenue growth. Technicals reveal the price above 50- and 200-day moving averages, supporting a short-term rebound setup. Confirming a bounce requires a volume surge above average and a break past €17.80 resistance. Meyka AI assigns a B-grade hold rating and forecasts 21.2% upside to €20.85 within 12 months. Mixed analyst views persist, including a strong sell recommendation from third-party ratings. Investors should monitor liquidity and fundamental risks amid volatile earnings in this Consumer Cyclical player.
Go toTop